Moneycontrol Be a Pro
Get App
Last Updated : Nov 26, 2019 11:20 AM IST | Source: Moneycontrol.com

Glenmark Pharma share price declines 3%

The share price dropped even after the FDA gave approval for Metformin Hydrochloride extended‐release tablets used for managing type-two diabetes

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Glenmark Pharma share price declined 3 percent intraday on November 26 even after the company got United States Food & Drug Administration (USFDA) approval for Metformin Hydrochloride extended‐release tablets used for managing type-two diabetes.

The FDA gave the go-ahead to Glenmark Pharmaceuticals Inc, USA, for Metformin Hydrochloride extended‐release tablets USP, 500 mg and 1,000 mg, the generic version of Glumetza of Salix Pharmaceuticals Inc.

According to IQVIATM sales data for the 12‐month period ending September 2019, the Glumetza 500 mg and 1000 mg tablets achieved annual sales of around $226.7 million.

Close

The company's current portfolio consists of 164 products authorised for distribution in the US marketplace and 44 ANDA’s pending approval with the US FDA.

At 1050 hours, Glenmark Pharma was quoting at Rs 340.45, down Rs 9.15, or 2.62 percent, on the BSE.

LIVE NOW... Video series on How to Double Your Monthly Income... where Rahul Shah, Ex-Swiss Investment Banker and one of India's leading experts on wealth building, reveals his secret strategies for the first time ever. Register here to watch it for FREE.
First Published on Nov 26, 2019 11:20 am
Loading...
Follow us on
Available On